Lupin Launches Ganirelix Acetate Injection in US - Fertility Treatment
Feb 15, 2024 14:06
Lupin launches Ganirelix Acetate injection in the US, a generic for fertility treatments, approved by the USFDA. The injection inhibits premature LH surges during controlled ovarian hyperstimulation.
New Delhi, Feb 15 (PTI) Pharma major Lupin Ltd on Thursday said it has launched Ganirelix Acetate injection indicated to women undergoing certain fertility treatments following approval from the US health regulatory.
The US Food and Drug Administration (USFDA) had approved Ganirelix Acetate injection, 250 mcg/0.5 mL, single-dose prefilled syringe and the same has been launched in the US market, Lupin said in a regulatory filing.
It is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.
The injection is indicated for the inhibition of premature Luteinizing Hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate injection had estimated annual sales of USD 87 million in the US, Lupin said citing IQVIA MAT December 2023 data.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.